RAC2 and neoplasm: Bone metastasis inhibitor zoledronic acid has the potential to prevent prenylation of small-G proteins by inhibition of farnesyl-diphosphate synthase [12], suggesting the anticancer effect of the agent not only on the metastases, but directly on the primary tumor as well.